Epigral is building scale; qualification will decide the returns
Epigral’s Q1 revenue rose 15% to Rs 709 crore, but gross and EBITDA margins narrowed. The company is expanding CPVC, epichlorohydrin and epoxy capacity. The strategic goal is to lift derivatives and specialties from about 52% of revenue to roughly 70% by FY28. Customer qualification and utilisation will decide whether the mix shift pays.
ROCE has already fallen to 16% as projects build. Watch commissioning, approved grades, repeat orders, spreads and cash flow—not capacity announcements alone.
The real milestone is a qualified product sold repeatedly at a spread that restores returns on the capital now being installed.
For full access and more such stories, register at https://indianpetrochem.com/registration